Press releases

STOCKHOLM — November 24, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the company has finalized the program for the upcoming virtual capital markets day for investors, analysts and journalists on November 30[th], 2020. The program is available on the company´s website at: www.oncopeptides.com/en/calendar/ (https://oncopeptides.se/en/calendar/)

Summary Financial overview July 1 – September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3)

STOCKHOLM — November 5, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company will arrange a virtual capital markets day for investors, analysts and journalists on November 30[th], 2020. The program will be published on the company´s website during the week of November 23 at: www.oncopeptides.com/en/calendar/ (https://oncopeptides.se/en/calendar/)

STOCKHOLM — November 4, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focusing on the development of targeted therapies for difficult-to-treat hematological diseases, today announced that twelve abstracts, including one oral presentation, have been accepted for the upcoming virtual American Society of Hematology (ASH) meeting on December 5-8, 2020. Key clinical abstracts focus on data from the ongoing phase 1/2 ANCHOR combination study and the pivotal phase 2 HORIZON study. The preclinical abstracts further explore the mechanism of action of the proprietary peptide-drug conjugate platform in multidrug resistant models of multiple myeloma. The abstracts are published online today at https://www.hematology.org/meetings/annual-meeting/abstracts

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting on Friday 4 December 2020

STOCKHOLM — October 21, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the composition of the Nomination Committee for the Annual General Meeting 2021 has been established. The Nomination Committee consists of the following persons who together represent approximately 34 percent of the number of shares and votes in the company, based on the shareholder information by the end of September

STOCKHOLM — October 19, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 - a second drug candidate based on the proprietary Peptide Drug Conjugate platform (PDC)

STOCKHOLM — October 14, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company has entered into a loan agreement with the European Investment Bank (EIB), granting the company access to an unsecured loan facility of up to €40 M. The loan may be used to further support the clinical development of melflufen, and the company’s transition from a R&D company into a fully integrated global biopharmaceutical company

STOCKHOLM — October 12, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has informed the European Medicines Agency, EMA, about its intention to submit an application for a conditional marketing authorization of melflufen (INN melphalan flufenamide) in the EU, based on the pivotal phase 2 HORIZON study in relapsed refractory multiple myeloma (RRMM)

STOCKHOLM — October 1, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the open-label Expanded Access Program, sEAPort (https://oncopeptides-us.com/en/expanded-access-program/), for eligible U.S. patients, is formally open. Melflufen (INN melphalan flufenamide), is currently being evaluated in several clinical studies as a treatment for patients with triple-class refractory multiple myeloma. The sEAPort program is available to adults, age 18 and older, who have received at least two prior lines of therapy and whose multiple myeloma is refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients)